Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 3 Carcinoma, Non-Small-Cell Lung 3 Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Leukemia, Hairy Cell 2 Xanthogranuloma, Juvenile 1 Wilms Tumor 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Noonan syndrome 3 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Medulloblastoma 1 Histiocytosis, Langerhans-Cell 1 Histiocytic Sarcoma 1 Hepatoblastoma 1 Glioma 1 Genomic Instability 1 Ependymoma 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Genomic Instability × Vemurafenib × 90 days × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡